PEGANONE- ethotoin tablet Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

peganone- ethotoin tablet

recordati rare diseases, inc. - ethotoin (unii: 46qg38nc4u) (ethotoin - unii:46qg38nc4u) - ethotoin 250 mg - peganone (ethotoin tablets, usp) is indicated for the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures. peganone (ethotoin tablets, usp) is contraindicated in patients with hepatic abnormalities or hematologic disorders.

DESOXYN- methamphetamine hydrochloride tablet Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

desoxyn- methamphetamine hydrochloride tablet

recordati rare diseases, inc. - methamphetamine hydrochloride (unii: 997f43z9cv) (methamphetamine - unii:44ral3456c) - methamphetamine hydrochloride 5 mg - attention deficit disorder with hyperactivity: desoxyn tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. in patients known to be hypersensitive to amphetamine, or other components of desoxyn. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine p

Sylvant Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sylvant

pharmacy retailing (nz) ltd t/a healthcare logistics - siltuximab 100mg;  ;   - powder for infusion concentrate - 100 mg - active: siltuximab 100mg     excipient: histidine polysorbate 80 sucrose - sylvant is indicated for the treatment of adult patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.

Sylvant Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sylvant

pharmacy retailing (nz) ltd t/a healthcare logistics - siltuximab 400mg;  ;   - powder for infusion concentrate - 400 mg - active: siltuximab 400mg     excipient: histidine polysorbate 80 sucrose - sylvant is indicated for the treatment of adult patients with multicentric castleman's disease (mcd) who are human immunodeficiency virus (hiv) negative and human herpesvirus-8 (hhv-8) negative.

QARZIBA dinutuximab beta 4.5 mg/mL concentrate for solution for infusion, 20 mg/4.5 mL vial Australija - engleski - Department of Health (Therapeutic Goods Administration)

qarziba dinutuximab beta 4.5 mg/ml concentrate for solution for infusion, 20 mg/4.5 ml vial

recordati rare diseases australia pty ltd - dinutuximab beta, quantity: 4.5 mg/ml - solution - excipient ingredients: polysorbate 20; hydrochloric acid; sucrose; water for injections; histidine - qarziba is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.

Zanidip Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

zanidip

viatris limited - lercanidipine hydrochloride 10mg;   - film coated tablet - 10 mg - active: lercanidipine hydrochloride 10mg   excipient: hypromellose iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate povidone powdered cellulose purified talc sodium starch glycolate titanium dioxide - zanidip is indicated for the treatment of mild to moderate hypertension.